44. Wegener granulomatosis Clinical trials / Disease details
Clinical trials : 92 / Drugs : 106 - (DrugBank : 27) / Drug target genes : 22 - Drug target pathways : 78
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01405807 (ClinicalTrials.gov) | February 2011 | 27/7/2011 | Alemtuzumab for ANCA Associated Refractory Vasculitis | Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy | Vasculitis;Microscopic Polyangiitis;Granulomatosis With Polyangiitis;Wegener's | Drug: Alemtuzumab | Cambridge University Hospitals NHS Foundation Trust | NULL | Recruiting | 18 Years | 60 Years | Both | 24 | Phase 4 | United Kingdom |